What is the half-life of NPH (Neutral Protamine Hagedorn) insulin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of NPH Insulin

NPH (Neutral Protamine Hagedorn) insulin has a half-life of approximately 6.6 hours, with its peak effect occurring around 8-12 hours after injection and a total duration of action of about 18-24 hours. 1, 2

Pharmacokinetic Profile of NPH Insulin

  • NPH insulin begins to lower blood glucose approximately 1-2 hours after subcutaneous injection 1
  • Peak effect occurs at approximately 8-12 hours after injection 3, 1
  • Total duration of action is approximately 18-24 hours, with studies showing a range of 20-29 hours 1
  • The half-life of NPH insulin in subcutaneous tissue has been measured at 6.6 ± 3.3 hours 2

Clinical Implications of NPH Pharmacokinetics

Advantages

  • Intermediate-acting profile makes it suitable for basal insulin coverage
  • Can be administered once or twice daily depending on patient needs
  • Can be mixed with short-acting or rapid-acting insulins for combined coverage 3, 4

Disadvantages

  • The pronounced peak at 8-12 hours increases risk of hypoglycemia, particularly when administered at bedtime 3
  • More variable absorption compared to newer basal insulin analogs
  • In elderly patients, NPH has been associated with higher rates of hypoglycemia compared to basal-bolus regimens with insulin analogs 3, 4

Practical Applications

Dosing Considerations

  • When used as basal insulin, NPH is typically administered as:
    • Once daily: Usually in the morning or at bedtime
    • Twice daily: Typically 2/3 in the morning and 1/3 in the evening 4
  • Initial dosing can start at 0.1-0.2 units/kg per day with titration based on glucose patterns 4

Mixing Guidelines

  • NPH can be mixed with rapid-acting or short-acting insulins 3, 4
  • When mixed with rapid-acting insulin, the mixture should be injected within 15 minutes before a meal 3, 4
  • NPH should NOT be mixed with lente insulins due to potential precipitation of zinc phosphate 3, 4
  • Currently available NPH and short-acting insulin formulations when mixed may be used immediately or stored for future use 3

Important Considerations

  • The pronounced peak of NPH insulin at 8-12 hours can lead to nocturnal hypoglycemia when administered at bedtime 3, 5
  • Newer long-acting insulin analogs (like insulin glargine) offer a smoother time-action profile with less pronounced peaks compared to NPH 5, 6
  • Storage conditions affect potency: NPH insulin should be stored according to manufacturer guidelines, typically refrigerated when not in use 3
  • Visual inspection before use is important: NPH insulin should appear uniformly cloudy; any clumping, frosting, precipitation, or change in clarity may indicate loss of potency 3

Clinical Pitfalls to Avoid

  • Assuming NPH has a consistent effect throughout its duration of action (it has a pronounced peak)
  • Failing to account for the peak action when timing doses relative to meals and sleep
  • Overlooking the increased hypoglycemia risk in elderly patients using NPH compared to newer insulin analogs 3, 4
  • Inappropriate mixing with other insulin types (particularly lente insulins) 3, 4

References

Research

Time-action characteristics of regular and NPH insulin in insulin-treated diabetics.

The Journal of clinical endocrinology and metabolism, 1980

Research

Kinetics of subcutaneous NPH insulin in diabetics.

Clinical pharmacology and therapeutics, 1982

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Insulin Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Insulin glargine versus NPH insulin in patients with type 1 diabetes.

Drugs of today (Barcelona, Spain : 1998), 2003

Research

Insulin glargine.

Drugs, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.